Matrix metalloproteinase −12: A marker of preeclampsia?

Yakovleva, Natalya Yu.; Saprykina, D; Vasiljeva, E; Bettikher, O; Godzoeva, A; Kazantseva, T; Zazerskaya, I

doi:10.1016/j.placenta.2022.09.003

Cited by 2 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study adds information on the association between decreased MMP-12 levels in early mid-pregnancy and later development of preeclampsia. However, a recent study found lower levels of MMP-12 during gestational weeks 11–13 in women who later developed preeclampsia, than were found in those who continued to have a normotensive pregnancy [ 21 ]. Interestingly, they found an increase of MMP-12 between the first and second (22–24 weeks) trimester in women with subsequent preeclampsia.…”

Section: Discussionmentioning

confidence: 99%

“…Preeclampsia and cardiovascular disease share pathophysiological entities and risk factors, making cardiovascular predictive biomarkers for preeclampsia an interesting topic for investigation. Cardiovascular biomarkers have to some extent been explored in pregnant women, both before clinical symptoms and at the time of manifest preeclampsia [20][21][22]. In longitudinal studies, early-and late-onset preeclampsia have shown a distinct cardiovascular profile before and throughout pregnancy, e.g., differences in cardiac output and vascular resistance to name a few [23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study

Callbo,

Junus,

Gabrysch

et al. 2024

Reprod. Sci.

View full text Add to dashboard Cite

Prediction of women at high risk of preeclampsia is important for prevention and increased surveillance of the disease. Current prediction models need improvement, particularly with regard to late-onset preeclampsia. Preeclampsia shares pathophysiological entities with cardiovascular disease; thus, cardiovascular biomarkers may contribute to improving prediction models. In this nested case-control study, we explored the predictive importance of mid-pregnancy cardiovascular biomarkers for subsequent preeclampsia. We included healthy women with singleton pregnancies who had donated blood in mid-pregnancy (~ 18 weeks’ gestation). Cases were women with subsequent preeclampsia (n = 296, 10% of whom had early-onset preeclampsia [< 34 weeks]). Controls were women who had healthy pregnancies (n = 333). We collected data on maternal, pregnancy, and infant characteristics from medical records. We used the Olink cardiovascular II panel immunoassay to measure 92 biomarkers in the mid-pregnancy plasma samples. The Boruta algorithm was used to determine the predictive importance of the investigated biomarkers and first-trimester pregnancy characteristics for the development of preeclampsia. The following biomarkers had confirmed associations with early-onset preeclampsia (in descending order of importance): placental growth factor (PlGF), matrix metalloproteinase (MMP-12), lectin-like oxidized LDL receptor 1, carcinoembryonic antigen-related cell adhesion molecule 8, serine protease 27, pro-interleukin-16, and poly (ADP-ribose) polymerase 1. The biomarkers that were associated with late-onset preeclampsia were BNP, MMP-12, alpha-L-iduronidase (IDUA), PlGF, low-affinity immunoglobulin gamma Fc region receptor II-b, and T cell surface glycoprotein. Our results suggest that MMP-12 is a promising novel preeclampsia biomarker. Moreover, BNP and IDUA may be of value in enhancing prediction of late-onset preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study

Callbo,

Junus,

Gabrysch

et al. 2024

Reprod. Sci.

View full text Add to dashboard Cite

show abstract

“…However, the existing studies only measured the levels of MMPs in part of the pregnancy and did not analyze MMP levels throughout the whole pregnancy, which in turn lacks a longitudinal consistency and has limitations in clinical applications [ 16 , 17 , 18 ]. To address these shortcomings, we detected the serum levels of MMP-2, MMP-7 and MMP-9 in pre-eclampsia patients as well as normal pregnant women throughout pregnancy by the enzyme-linked immunosorbent assay (ELISA).…”

Section: Introductionmentioning

confidence: 99%

Expression of Matrix Metalloproteinase-2,-7,-9 in Serum during Pregnancy in Patients with Pre-Eclampsia: A Prospective Study

Bahabayi

Yang

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: Matrix Metalloproteinases (MMPs) have been found to have important roles in vascular pathology and may be involved in the occurrence of pre-eclampsia. In this study, the serum levels of MMP-2, -7, -9 in normal pregnant women and pre-eclampsia patients were analyzed to assess their predictive value. Methods: A total of 1563 pregnant women from Peking University Third Hospital, from February 2021 to October 2021, were enrolled. Serum samples were collected from patients one to three times, during the different trimesters. Among the 102 singleton pre-eclampsia patients, we collected samples from 33 patients in the first trimester (6–13 GW), 33 in the second trimester (14–28 GW), 41 in the third trimester (29–41 GW) and 28 after onset of pre-eclampsia. Samples from each trimester were collected before the onset of pre-eclampsia. Then we selected 35, 37, 43 and 25 samples from 124 healthy pregnant women by matching their age, BMI and gestational weeks, using these as the control groups. Serum levels of MMP-2, -7, -9 were detected by ELISA. The receiver operating characteristic (ROC) curve was used to evaluate their predictive value. Results: Except for the first trimester, MMP-2 and MMP-7 were significantly higher in the pre-eclampsia group (p < 0.5). Additionally, in the pre-eclampsia group, MMP-9 increased significantly in the first trimester and after the onset of pre-eclampsia but decreased significantly in the second and third trimesters (p < 0.5). The ROC curve indicated that MMP-9, MMP-2 and MMP-7 were the best indicators for predicting pre-eclampsia in the first, second and third trimesters, respectively. Conclusion: Increased MMP-2 and MMP-7 levels and a decreased MMP-9 level seem to be related to the pathogenesis of pre-eclampsia and are expected to be potential predictors of pre-eclampsia.

show abstract

Matrix metalloproteinase −12: A marker of preeclampsia?

Cited by 2 publications

References 13 publications

Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study

Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study

Expression of Matrix Metalloproteinase-2,-7,-9 in Serum during Pregnancy in Patients with Pre-Eclampsia: A Prospective Study

Contact Info

Product

Resources

About